Cambridge Healthtech Institute’s 13th Annual

Advances in Drug Metabolism & Safety Testing

Optimizing Drug Metabolism, Predicting Drug Toxicity, Assessing New Drug Modalities

June 2-4, 2020

 

Lead compounds in drug discovery need to be optimized for both efficacy and safety. Unfortunately, some of the adverse events related to metabolism, clearance, transport and drug-drug interactions do not surface until much later in development. Similarly, cardiotoxicity, hepatotoxicity and idiosyncratic drug toxicity continue to haunt the drug development process. While new screening technologies, in vitro assays, in vivo models and computational tools are being developed and used, scientists are still unclear about when, where and which tools to use, how reliable the data is, and how predictive the translation is from in vitro to in vivo. Cambridge Healthtech Institute’s Advances in Drug Metabolism & Safety Testing conference looks at the scientific and technological progress being made to optimize lead compounds and predict drug-induced toxicities early in drug discovery, and to better translate these findings to the clinic. The talks and discussions highlight relevant case studies, recent research findings, and the use of innovative assays and technologies for improving drug safety.   

 

Coverage will include, but is not limited to:

 

Optimizing Drug Metabolism

  • Impact of structure-activity relationships on ADMET properties
  • Drug metabolism and role of reactive drug metabolites     
  • Drug transporters, drug clearance and drug-drug interactions
  • Monitoring biotransformation and tissue concentrations

 

Predicting PKPD and Drug Toxicity

  • Leveraging in silico tools and machine learning for ADMET predictions     
  • PKPD modeling and predictions 
  • Early Prediction of Human Dosing and Drug Distribution     
  • Using 3D cultures, iPS cells, microphysiological systems to predict drug toxicity

 

Assessing New Drug Modalities

  • ADME for new drug modalities: ADCs, bispecifics, PROTACs, macrocyclics and more
  • Developing new assays, models and technologies to optimize leads      
  • Evaluating off-target drug promiscuity     
  • Assessing immunogenicity and drug-induced toxicity

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is November 22, 2019.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

For more details on the conference, please contact:
Tanuja Koppal, PhD

Senior Conference Director,

Cambridge Healthtech Institute

Email: tkoppal@healthtech.com

 

For partnering and sponsorship information, please contact:

Companies A-K
Rod Eymael
Manager, Business Development
Phone: 781-247-6286
Email: reymael@healthtech.com

 

Companies L-Z
Joseph Vacca, MS
Director, Business Development
Phone: 781-972-5431
Email: jvacca@healthtech.com